Tse-Ling Fong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tse-Ling Fong has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Mimi Chang
Asian Pacific Liver Center at Saint Vincent Medical Center Los Angeles California USA
6 shared publicationsAndy Tien
5 shared publicationsCarolina Lim
Asian Pacific Liver Center at Saint Vincent Medical Center Los Angeles California USA
4 shared publicationsYong W. Cho
Liver Transplantation Program, Keck School of Medicine, University of Southern California, Los Angeles, CA
4 shared publications- Brian T. Lee
Liver Program, Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, CA
3 shared publications David R. Braxton
Department of Pathology, Hoag Memorial Hospital Presbyterian, Newport Beach, USA
3 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-10
Vorasidenib-Induced Acute Liver Injury
- 11 September 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-10
Open AccessVorasidenib-Induced Acute Liver Injury
- Open Access
- 16 March 2026
- Published by Springer Nature in Journal of Immigrant and Minority Health
Clinical Characteristics of Metabolic Dysfunction Steatotic Liver Disease in Asian-American Patients with Chronic Hepatitis B
The aim of this project was to determine the prevalence of fatty liver among Asian-American patients with chronic hepatitis B in a real-world setting, and to characterize the demographic, body composition and clinical features of these patients. This was a retrospective cross-sectional study of 115 Asian-American CHB patients followed at two clinical liver disease community programs in Southern California. Patients underwent standardized interviews, physical exams, body composition analysis (InBody® scan), laboratory studies, and assessment of liver stiffness and fat by FibroScan®. The median BMI of the cohort was 24.4 kg/m 2 , CAP was 250 dB/m, and liver stiffness was 5.0 kPa. Patients whose BMI were > 23 kg/m 2 showed a significant increase in hepatic steatosis, percent body fat, years lived in the US, prevalence and number of metabolic syndrome components (obesity, hypertension, type 2 diabetes mellitus). Asians who immigrate to the US at a younger age have an increased risk of elevated BMI and consequent risk of MASLD. Body composition and liver disease progression differences across BMI in our cohort support the need for population-specific anthropometric parameters and underscores a BMI of 23 kg/m 2 as an important cutoff point in characterizing progressive liver disease in Asian-Americans with CHB. The increased risk of MASLD seen in our cohort may be due to the impact of acculturation.
- 16 March 2026
- Published by Springer Nature in Journal of Immigrant and Minority Health
Open AccessClinical Characteristics of Metabolic Dysfunction Steatotic Liver Disease in Asian-American Patients with Chronic Hepatitis B
The aim of this project was to determine the prevalence of fatty liver among Asian-American patients with chronic hepatitis B in a real-world setting, and to characterize the demographic, body composition and clinical features of these patients. This was a retrospective cross-sectional study of 115 Asian-American CHB patients followed at two clinical liver disease community programs in Southern California. Patients underwent standardized interviews, physical exams, body composition analysis (InBody® scan), laboratory studies, and assessment of liver stiffness and fat by FibroScan®. The median BMI of the cohort was 24.4 kg/m 2 , CAP was 250 dB/m, and liver stiffness was 5.0 kPa. Patients whose BMI were > 23 kg/m 2 showed a significant increase in hepatic steatosis, percent body fat, years lived in the US, prevalence and number of metabolic syndrome components (obesity, hypertension, type 2 diabetes mellitus). Asians who immigrate to the US at a younger age have an increased risk of elevated BMI and consequent risk of MASLD. Body composition and liver disease progression differences across BMI in our cohort support the need for population-specific anthropometric parameters and underscores a BMI of 23 kg/m 2 as an important cutoff point in characterizing progressive liver disease in Asian-Americans with CHB. The increased risk of MASLD seen in our cohort may be due to the impact of acculturation.
- Open Access
- 19 December 2025
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 13 (4) , e81240047
Associations between Eating Behaviors, Body Composition, and Mental Health in Asian and White Adults with Metabolic Dysfunction-associated Steatotic Liver Disease
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is affected by metabolic, psychological, and behavioral factors, with potential differences in pathophysiological pathways across racial groups. Objective This study aims to investigate the relationship between eating behaviors, emotional functioning, and anthropometric differences in Asian and maintain at various stages of liver disease. Methods A retrospective analysis was conducted on 98 MASLD patients (70 White and 28 Asian) from a Southern California liver clinic. Participants completed validated questionnaires assessing depressive and anxiety symptoms, eating behaviors, and quality of life. Body composition was measured using bioelectrical impedance analysis, and liver health was assessed through transient elastography. Multivariate regression and mediation analyses examined associations and pathways among psychological, behavioral, and clinical variables, with race as a moderator. Results White participants had higher body mass index (BMI) and body fat percentage, but liver steatosis and stiffness were similar between groups. In Asians, hepatic steatosis correlated most strongly with body fat mass, whereas in Whites, emotional eating was more closely linked to BMI and body fat percentage compared to Asians. Whites reported higher anxiety and lower quality of life. Emotional eating was associated with hepatic steatosis in both groups, but only in Whites did BMI and percent body fat mediate this relationship. Among Asians, emotional eating was linked to liver fat independent of body composition. Conclusion Distinct racial pathways exist in MASLD progression, with Asians potentially developing fatty liver without overt body fat changes. These findings highlight the need for tailored diagnostic and clinical strategies that consider metabolic, behavioral, and psychological differences across racial groups.
- 19 December 2025
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 13 (4) , e81240047
Open AccessAssociations between Eating Behaviors, Body Composition, and Mental Health in Asian and White Adults with Metabolic Dysfunction-associated Steatotic Liver Disease
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is affected by metabolic, psychological, and behavioral factors, with potential differences in pathophysiological pathways across racial groups. Objective This study aims to investigate the relationship between eating behaviors, emotional functioning, and anthropometric differences in Asian and maintain at various stages of liver disease. Methods A retrospective analysis was conducted on 98 MASLD patients (70 White and 28 Asian) from a Southern California liver clinic. Participants completed validated questionnaires assessing depressive and anxiety symptoms, eating behaviors, and quality of life. Body composition was measured using bioelectrical impedance analysis, and liver health was assessed through transient elastography. Multivariate regression and mediation analyses examined associations and pathways among psychological, behavioral, and clinical variables, with race as a moderator. Results White participants had higher body mass index (BMI) and body fat percentage, but liver steatosis and stiffness were similar between groups. In Asians, hepatic steatosis correlated most strongly with body fat mass, whereas in Whites, emotional eating was more closely linked to BMI and body fat percentage compared to Asians. Whites reported higher anxiety and lower quality of life. Emotional eating was associated with hepatic steatosis in both groups, but only in Whites did BMI and percent body fat mediate this relationship. Among Asians, emotional eating was linked to liver fat independent of body composition. Conclusion Distinct racial pathways exist in MASLD progression, with Asians potentially developing fatty liver without overt body fat changes. These findings highlight the need for tailored diagnostic and clinical strategies that consider metabolic, behavioral, and psychological differences across racial groups.
- Open Access
- 4 January 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (3) , 1004-1014
Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature
Background and aims Pseudocirrhosis is a poorly understood acquired morphologic change of the liver that occurs in the setting of metastatic malignancy and radiographically resembles cirrhosis. Pseudocirrhosis has been primarily described in metastatic breast carcinoma, with few case reports arising from other primary malignancies. We present 29 cases of pseudocirrhosis, including several cases from primary malignancies not previously described. Methods Radiologic, clinical, demographic, and biomedical data were collected retrospectively and analyzed. We compared clinical and radiologic characteristics and outcomes between patients with pseudocirrhosis arising in metastatic breast cancer and non-breast primary malignancies. Results Among the 29 patients, 14 had breast cancer and 15 had non-breast primaries including previously never reported primaries associated with pseudocirrhosis, melanoma, renal cell carcinoma, appendiceal carcinoid, and cholangiocarcinoma. Median time from cancer diagnosis to development of pseudocirrhosis was 80.8 months for patients with primary breast cancer and 29.8 months for non-breast primary (p = 0.02). Among all patients, 15 (52%) had radiographic features of portal hypertension. Radiographic evidence of portal hypertension was identified in 28.6% of breast cancer patients, compared to 73.3% of those with non-breast malignancies (p = 0.03). Conclusion Pseudocirrhosis has most commonly been described in the setting of metastatic breast cancer but occurs in any metastatic disease to the liver. Our study suggests that portal hypertensive complications are more common in the setting of non-breast primary cancers than in metastatic breast cancer. Prior exposure to multiple chemotherapeutic agents, and agents known to cause sinusoidal injury, is a common feature but not essential for the development of pseudocirrhosis.
- 4 January 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (3) , 1004-1014
Open AccessPseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature
Background and aims Pseudocirrhosis is a poorly understood acquired morphologic change of the liver that occurs in the setting of metastatic malignancy and radiographically resembles cirrhosis. Pseudocirrhosis has been primarily described in metastatic breast carcinoma, with few case reports arising from other primary malignancies. We present 29 cases of pseudocirrhosis, including several cases from primary malignancies not previously described. Methods Radiologic, clinical, demographic, and biomedical data were collected retrospectively and analyzed. We compared clinical and radiologic characteristics and outcomes between patients with pseudocirrhosis arising in metastatic breast cancer and non-breast primary malignancies. Results Among the 29 patients, 14 had breast cancer and 15 had non-breast primaries including previously never reported primaries associated with pseudocirrhosis, melanoma, renal cell carcinoma, appendiceal carcinoid, and cholangiocarcinoma. Median time from cancer diagnosis to development of pseudocirrhosis was 80.8 months for patients with primary breast cancer and 29.8 months for non-breast primary (p = 0.02). Among all patients, 15 (52%) had radiographic features of portal hypertension. Radiographic evidence of portal hypertension was identified in 28.6% of breast cancer patients, compared to 73.3% of those with non-breast malignancies (p = 0.03). Conclusion Pseudocirrhosis has most commonly been described in the setting of metastatic breast cancer but occurs in any metastatic disease to the liver. Our study suggests that portal hypertensive complications are more common in the setting of non-breast primary cancers than in metastatic breast cancer. Prior exposure to multiple chemotherapeutic agents, and agents known to cause sinusoidal injury, is a common feature but not essential for the development of pseudocirrhosis.
- 30 October 2023
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 6 (3) , 363-371
Combination vardenifil and tadalifil drug induced liver injury; case report and review of the literature of liver injury associated with phosphodiesterase type 5 inhibitors
Background: Phosphodiesterase type 5 inhibitors (PDE5I) are prescribed for erectile dysfunction and pulmonary hypertension. Despite its widespread use, there are only seven cases of drug-induced liver injury (DILI) associated with PDE5I, none associated with vardenafil or avanafil. We report a patient who had taken vardenafil and tadalafil individually for several years without developing symptoms of liver injury. However, after taking vardenafil and tadalafil together on 2 consecutive days, he developed severe cholestasis. Methods: Causality was determined using Roussel Uclaf causality assessment method (RUCAM). Results: The patient is a 72-year-old White man in excellent health who drank 2 units of alcohol, three times/week. Previously, he had used vardenafil for more than 2 years and tadalafil for 3 months as single agent for erectile dysfunction without any complications. He took vardenafil and tadalafil for 2 consecutive days and 5 days later, he developed dyspepsia, loss of appetite, jaundice, and intense itching. Liver tests showed mixed cholestatic/hepatocellular pattern of injury. Histology showed marked cholestasis with minimal inflammation. He remained cholestatic for 5 weeks before a full recovery 2 months later. The patient then resumed vardenafil monotherapy with no recurrent liver dysfunction. RUCAM causality score 7 indicates that the combination of PDE5I is probable cause of liver injury. The similarities among the eight cases of PDE5I DILI include a relatively short latency, cholestatic histological features, and complete recovery. Biochemical pattern of liver injury is variable. Conclusions: PDE5I DILI is a rare event that can result in severe acute liver injury.
- 30 October 2023
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 6 (3) , 363-371
Combination vardenifil and tadalifil drug induced liver injury; case report and review of the literature of liver injury associated with phosphodiesterase type 5 inhibitors
Background: Phosphodiesterase type 5 inhibitors (PDE5I) are prescribed for erectile dysfunction and pulmonary hypertension. Despite its widespread use, there are only seven cases of drug-induced liver injury (DILI) associated with PDE5I, none associated with vardenafil or avanafil. We report a patient who had taken vardenafil and tadalafil individually for several years without developing symptoms of liver injury. However, after taking vardenafil and tadalafil together on 2 consecutive days, he developed severe cholestasis. Methods: Causality was determined using Roussel Uclaf causality assessment method (RUCAM). Results: The patient is a 72-year-old White man in excellent health who drank 2 units of alcohol, three times/week. Previously, he had used vardenafil for more than 2 years and tadalafil for 3 months as single agent for erectile dysfunction without any complications. He took vardenafil and tadalafil for 2 consecutive days and 5 days later, he developed dyspepsia, loss of appetite, jaundice, and intense itching. Liver tests showed mixed cholestatic/hepatocellular pattern of injury. Histology showed marked cholestasis with minimal inflammation. He remained cholestatic for 5 weeks before a full recovery 2 months later. The patient then resumed vardenafil monotherapy with no recurrent liver dysfunction. RUCAM causality score 7 indicates that the combination of PDE5I is probable cause of liver injury. The similarities among the eight cases of PDE5I DILI include a relatively short latency, cholestatic histological features, and complete recovery. Biochemical pattern of liver injury is variable. Conclusions: PDE5I DILI is a rare event that can result in severe acute liver injury.
- Open Access
- 24 March 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (4)
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system
Background: Chronic hepatitis B (HBV) prevalence is highest in foreign-born Asian and African individuals in the US, though Hispanics make up the largest proportion of the immigrant population. Differences in the diagnosis and management of chronic HBV in Hispanics might exist due to the lower awareness of risk. We aim to examine racial/ethnic disparities in the diagnosis, presentation, and immediate management of chronic HBV in a diverse safety net system enriched for Hispanics. Methods: In a large urban safety-net hospital system, we retrospectively identified patients with chronic HBV by serological data and categorized them into mutually exclusive self-identified racial/ethnic groups: Hispanics, Asians, Blacks, and Whites. We then examined differences in screening, disease phenotype and severity, follow-up testing, and referral by race/ethnicity. Results: Among 1063 patients, 302 (28%) were Hispanics, 569 (54%) Asians, 161 (15%) Blacks, and 31 (3%) Whites. More Hispanics (30%) were screened in the acute setting (defined as inpatient or emergency department encounters) than Asians (13%), Blacks (17%), or Whites (23%) (ppppp<0.01). Conclusion: Our results underscore the importance of raising chronic HBV awareness and increasing both screening and linkage to care among Hispanic immigrants in addition to the existing risk groups, with the goal of mitigating downstream liver-related complications.
- 24 March 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (4)
Open AccessDisparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system
Background: Chronic hepatitis B (HBV) prevalence is highest in foreign-born Asian and African individuals in the US, though Hispanics make up the largest proportion of the immigrant population. Differences in the diagnosis and management of chronic HBV in Hispanics might exist due to the lower awareness of risk. We aim to examine racial/ethnic disparities in the diagnosis, presentation, and immediate management of chronic HBV in a diverse safety net system enriched for Hispanics. Methods: In a large urban safety-net hospital system, we retrospectively identified patients with chronic HBV by serological data and categorized them into mutually exclusive self-identified racial/ethnic groups: Hispanics, Asians, Blacks, and Whites. We then examined differences in screening, disease phenotype and severity, follow-up testing, and referral by race/ethnicity. Results: Among 1063 patients, 302 (28%) were Hispanics, 569 (54%) Asians, 161 (15%) Blacks, and 31 (3%) Whites. More Hispanics (30%) were screened in the acute setting (defined as inpatient or emergency department encounters) than Asians (13%), Blacks (17%), or Whites (23%) (ppppp<0.01). Conclusion: Our results underscore the importance of raising chronic HBV awareness and increasing both screening and linkage to care among Hispanic immigrants in addition to the existing risk groups, with the goal of mitigating downstream liver-related complications.
- Open Access
- 3 February 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-6
Mifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature
Background: Mifepristone, also known as RU-486, is an anti-progestational steroid with similar chemical structure to anabolic steroids. Given as a single dose in conjunction with misoprostol, mifepristone is used to induce medical abortion. Mifepristone administered chronically at a higher dose is also approved for the management of hypercortisolism. There have been only 2 reported cases of mifepristone associated liver injury, in both cases, in the setting of Cushing syndrome. We report a third patient with Cushing syndrome with mifepristone induced liver injury with unique histological findings that provide insight to the pathophysiology of liver injury in mifepristone and anabolic steroids. Case presentation: Patient is a 63-year-old Caucasian female Cushing disease with no prior history of liver disease. She was started on mifepristone and semaglutide. Ninety days after initiating mifepristone, she developed deep jaundice, severe pruritus, fatigue, and nausea. Liver tests revealed a mixed hepatocellular/cholestatic pattern. Viral and autoimmune serologies were negative and there was no biliary dilatation on imaging. Liver biopsy showed severe cholestasis but no bile duct injury. Focal endothelialitis was present within a central venule. Cholestatic symptoms persisted for one month after presentation before slowly subsiding. Four months after stopping mifepristone, the patient’s symptoms completely resolved, and liver tests became normal. Compilation of Roussell Uclaf Causality Assessment Method score indicated probable causality. Conclusions: Mifepristone shares a similar chemical structure as synthetic anabolic/androgenic steroids and there are many similarities in the clinical presentation of liver injury. This case and the 2 other reported cases share similar clinical characteristics. The observation of endothelialitis in our patient may provide a mechanistic link between mifepristone, or anabolic steroids in general, and the development of vascular complications such as peliosis.
- 3 February 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-6
Open AccessMifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature
Background: Mifepristone, also known as RU-486, is an anti-progestational steroid with similar chemical structure to anabolic steroids. Given as a single dose in conjunction with misoprostol, mifepristone is used to induce medical abortion. Mifepristone administered chronically at a higher dose is also approved for the management of hypercortisolism. There have been only 2 reported cases of mifepristone associated liver injury, in both cases, in the setting of Cushing syndrome. We report a third patient with Cushing syndrome with mifepristone induced liver injury with unique histological findings that provide insight to the pathophysiology of liver injury in mifepristone and anabolic steroids. Case presentation: Patient is a 63-year-old Caucasian female Cushing disease with no prior history of liver disease. She was started on mifepristone and semaglutide. Ninety days after initiating mifepristone, she developed deep jaundice, severe pruritus, fatigue, and nausea. Liver tests revealed a mixed hepatocellular/cholestatic pattern. Viral and autoimmune serologies were negative and there was no biliary dilatation on imaging. Liver biopsy showed severe cholestasis but no bile duct injury. Focal endothelialitis was present within a central venule. Cholestatic symptoms persisted for one month after presentation before slowly subsiding. Four months after stopping mifepristone, the patient’s symptoms completely resolved, and liver tests became normal. Compilation of Roussell Uclaf Causality Assessment Method score indicated probable causality. Conclusions: Mifepristone shares a similar chemical structure as synthetic anabolic/androgenic steroids and there are many similarities in the clinical presentation of liver injury. This case and the 2 other reported cases share similar clinical characteristics. The observation of endothelialitis in our patient may provide a mechanistic link between mifepristone, or anabolic steroids in general, and the development of vascular complications such as peliosis.
- 26 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (2) , 429-437
The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation
Background.: Patients with compensated cirrhosis and chronic kidney disease are increasing along with demand for simultaneous liver kidney transplant (SLKT) and shortages of organs for transplantation. Although these well-compensated patients may not need a liver organ, the alternative of kidney transplant alone (KTA) poses the risk of liver decompensation. Therefore, we aim to characterize outcomes among patients with compensated cirrhosis and chronic kidney disease listed for SLKT or receiving KTA to inform clinical decisions. Methods.: The 2-part retrospective study included a national cohort of patients listed for SLKT in United Network for Organ Sharing from January 2003 to June 2019 with Child A cirrhosis, with model for end-stage liver disease <25, and receiving dialysis; and a cohort of patients who underwent KTA from 2004 to 2019 with Child A cirrhosis identified through a 4-center chart review. Waitlist outcomes (SLKT, death, and clinical improvement) and post-KTA liver decompensation and survival were evaluated in the cohorts, respectively. Results.: In the national SLKT cohort (N = 705, median age 56 y, 68.8% male), 5-y cumulative incidence of SLKT was 43.1%, death 32.1%, and clinical improvement 9.1%. Among SLKT recipients, 36.3% remained Child A without ascites or encephalopathy at transplant. In the local KTA cohort (N = 34, median age 54 y, 79.4% male), none had ascites or hepatic encephalopathy before KTA, but 15 had clinical portal hypertension. Five-y post-KTA incidence of liver decompensation was 36.8%, and survival was 89.2%. Conclusions.: SLKT may not be necessary for some patients with compensated cirrhosis needing kidney transplant. KTA is safe for selected patients with intact liver biochemical function, even with portal hypertension but without hepatic encephalopathy or ascites.
- 26 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (2) , 429-437
The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation
Background.: Patients with compensated cirrhosis and chronic kidney disease are increasing along with demand for simultaneous liver kidney transplant (SLKT) and shortages of organs for transplantation. Although these well-compensated patients may not need a liver organ, the alternative of kidney transplant alone (KTA) poses the risk of liver decompensation. Therefore, we aim to characterize outcomes among patients with compensated cirrhosis and chronic kidney disease listed for SLKT or receiving KTA to inform clinical decisions. Methods.: The 2-part retrospective study included a national cohort of patients listed for SLKT in United Network for Organ Sharing from January 2003 to June 2019 with Child A cirrhosis, with model for end-stage liver disease <25, and receiving dialysis; and a cohort of patients who underwent KTA from 2004 to 2019 with Child A cirrhosis identified through a 4-center chart review. Waitlist outcomes (SLKT, death, and clinical improvement) and post-KTA liver decompensation and survival were evaluated in the cohorts, respectively. Results.: In the national SLKT cohort (N = 705, median age 56 y, 68.8% male), 5-y cumulative incidence of SLKT was 43.1%, death 32.1%, and clinical improvement 9.1%. Among SLKT recipients, 36.3% remained Child A without ascites or encephalopathy at transplant. In the local KTA cohort (N = 34, median age 54 y, 79.4% male), none had ascites or hepatic encephalopathy before KTA, but 15 had clinical portal hypertension. Five-y post-KTA incidence of liver decompensation was 36.8%, and survival was 89.2%. Conclusions.: SLKT may not be necessary for some patients with compensated cirrhosis needing kidney transplant. KTA is safe for selected patients with intact liver biochemical function, even with portal hypertension but without hepatic encephalopathy or ascites.
- Open Access
- 12 July 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (5) , 2800-2807
Use of Liver Stiffness Measurements in Acute Decompensated Heart Failure: New Applications of a Non-Invasive Technique
Heart failure (HF) is a complex disease associated with multisystem organ failure, recurrent hospital admissions, and increased mortality. Acute decompensated heart failure (ADHF) increases central venous pressure (CVP) with resultant hepatic congestion, and this relationship has prognostic significance. The gold standard method of measuring CVP, right heart catheterization, is invasive and costly, prompting further investigation into more accurate non-invasive assessments in HF patients, including liver elastography. Liver elastography relies on imaging techniques to assess liver stiffness measurements (LSM), with high values equating to increased stiffness. While this was developed to assess fibrosis in liver disease, LSM also reflect increased CVP and hepatic congestion. Multiple studies involving ADHF patients, find that increased LSM are independently predictive of increased cardiac events, all-cause mortality, and worse post-operative outcome after both acute HF exacerbation and left ventricular assist device (LVAD) placement. In this review, we discuss the role of LSM as a surrogate for CVP and their applications in determining prognosis in both the ADHF and LVAD populations.
- 12 July 2022
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (5) , 2800-2807
Open AccessUse of Liver Stiffness Measurements in Acute Decompensated Heart Failure: New Applications of a Non-Invasive Technique
Heart failure (HF) is a complex disease associated with multisystem organ failure, recurrent hospital admissions, and increased mortality. Acute decompensated heart failure (ADHF) increases central venous pressure (CVP) with resultant hepatic congestion, and this relationship has prognostic significance. The gold standard method of measuring CVP, right heart catheterization, is invasive and costly, prompting further investigation into more accurate non-invasive assessments in HF patients, including liver elastography. Liver elastography relies on imaging techniques to assess liver stiffness measurements (LSM), with high values equating to increased stiffness. While this was developed to assess fibrosis in liver disease, LSM also reflect increased CVP and hepatic congestion. Multiple studies involving ADHF patients, find that increased LSM are independently predictive of increased cardiac events, all-cause mortality, and worse post-operative outcome after both acute HF exacerbation and left ventricular assist device (LVAD) placement. In this review, we discuss the role of LSM as a surrogate for CVP and their applications in determining prognosis in both the ADHF and LVAD populations.
- Open Access
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7) , S-1138-1138
783: INCIDENCE AND OUTCOMES OF COVID-19 IN POST-LIVER TRANSPLANT RECIPIENTS AFTER COVID-19 VACCINATION IN A LARGE INTEGRATED HEALTHCARE SYSTEM
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7) , S-1138-1138
Open Access783: INCIDENCE AND OUTCOMES OF COVID-19 IN POST-LIVER TRANSPLANT RECIPIENTS AFTER COVID-19 VACCINATION IN A LARGE INTEGRATED HEALTHCARE SYSTEM